Risperidone-induced neuroleptic malignant syndrome.
OBJECTIVE
To describe a patient with neuroleptic malignant syndrome (NMS) induced by risperidone, an atypical antipsychotic, and to review the available literature related to risperidone-associated NMS.


METHODS
Case report information was obtained from the resident physician and medical records. MEDLINE and Index Medicus were searched to obtain literature published between 1960 and 1995.


RESULTS
We report an adolescent boy who developed NMS after treatment with risperidone. Risperidone therapy was started after unsuccessful treatment and development of extrapyramidal adverse effects with haloperidol. The patient demonstrated the classic tetrad of fever, generalized skeletal muscle rigidity, altered mental status, and autonomic dysfunction. Risperidone was discontinued and the patient recovered after a prolonged hospital course with supportive management.


CONCLUSIONS
Clinicians are cautioned about the possibility of NMS with risperidone.
Sharma
R
R
Arnold and Marie Schwartz College of Pharmacy, Long Island University, NY, USA.
Trappler
B
B
Ng
Y K
YK
Leeman
C P
CP
D000293:Adolescent; D000547:Amantadine / Q000008:administration & dosage; D014150:Antipsychotic Agents / Q000009:adverse effects*; D001971:Bromocriptine / Q000008:administration & dosage; D015259:Dopamine Agents / Q000008:administration & dosage; D006801:Humans; D008297:Male; D009459:Neuroleptic Malignant Syndrome / Q000209:etiology*; D018967:Risperidone / Q000009:adverse effects*
D014150:Antipsychotic Agents; D015259:Dopamine Agents; D001971:Bromocriptine; D000547:Amantadine; D018967:Risperidone